Search Results - "Miguel F. Sanmamed"

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization by Sanmamed, Miguel F., Chen, Lieping

“…Harnessing an antitumor immune response has been a fundamental strategy in cancer immunotherapy. For over a century, efforts have primarily focused on…”
Get full text

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies by Chester, Cariad, Sanmamed, Miguel F., Wang, Jun, Melero, Ignacio

“…4-1BB (CD137, tumor necrosis factor receptor superfamily 9) is an inducible costimulatory receptor expressed on activated T and natural killer (NK) cells…”
Get full text

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes by Doroshow, Deborah B, Sanmamed, Miguel F, Hastings, Katherine, Politi, Katerina, Rimm, David L, Chen, Lieping, Melero, Ignacio, Schalper, Kurt A, Herbst, Roy S

“…Immune-checkpoint inhibitors (ICI), particularly inhibitors of the PD-1 axis, have altered the management of non-small cell lung cancer (NSCLC) over the last…”
Get full text

Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation by Sanmamed, Miguel F, Chen, Lieping

“…Immune evasion is an important hallmark of cancer, and a better understanding of this mechanism is essential for the development of effective strategies…”
Get full text

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy by Zhou, Ting, Damsky, William, Weizman, Orr-El, McGeary, Meaghan K., Hartmann, K. Patricia, Rosen, Connor E., Fischer, Suzanne, Jackson, Ruaidhri, Flavell, Richard A., Wang, Jun, Sanmamed, Miguel F., Bosenberg, Marcus W., Ring, Aaron M.

“…Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer, but they have only modest efficacy and limited…”
Get full text

Interleukin-8 in cancer pathogenesis, treatment and follow-up by Alfaro, Carlos, Sanmamed, Miguel F., Rodríguez-Ruiz, María E., Teijeira, Álvaro, Oñate, Carmen, González, Álvaro, Ponz, Mariano, Schalper, Kurt A., Pérez-Gracia, José L., Melero, Ignacio

“…•IL-8 is a chemokine frequently produced in the tumor microenvironment by human malignant cells.•IL-8 plays key roles in the immunobiology of human…”
Get full text

Direct Effects of Type I Interferons on Cells of the Immune System by HERVAS-STUBBS, Sandra, LUIS PEREZ-GRACIA, Jose, ROUZAUT, Ana, SANMAMED, Miguel F, LE BON, Agnes, MELERO, Ignacio

“…Type I interferons (IFN-I) are well-known inducers of tumor cell apoptosis and antiangiogenesis via signaling through a common receptor interferon alpha…”
Get full text

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis by Datar, Ila, Sanmamed, Miguel F, Wang, Jun, Henick, Brian S, Choi, Jungmin, Badri, Ti, Dong, Weilai, Mani, Nikita, Toki, Maria, Mejías, Luis D, Lozano, Maria D, Perez-Gracia, Jose Luis, Velcheti, Vamsidhar, Hellmann, Matthew D, Gainor, Justin F, McEachern, Kristen, Jenkins, David, Syrigos, Konstantinos, Politi, Katerina, Gettinger, Scott, Rimm, David L, Herbst, Roy S, Melero, Ignacio, Chen, Lieping, Schalper, Kurt A

“…To determine the tumor tissue/cell distribution, functional associations, and clinical significance of PD-1, LAG-3, and TIM-3 protein expression in human…”
Get full text

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs) by Alfaro, Carlos, Teijeira, Alvaro, Oñate, Carmen, Pérez, Guiomar, Sanmamed, Miguel F, Andueza, Maria Pilar, Alignani, Diego, Labiano, Sara, Azpilikueta, Arantza, Rodriguez-Paulete, Alfonso, Garasa, Saray, Fusco, Juan P, Aznar, Angela, Inogés, Susana, De Pizzol, Maria, Allegretti, Marcello, Medina-Echeverz, Jose, Berraondo, Pedro, Perez-Gracia, Jose L, Melero, Ignacio

“…Myeloid-derived suppressor cells (MDSC) are considered an important T-cell immunosuppressive component in cancer-bearing hosts. The factors that attract these…”
Get full text

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer by Schalper, Kurt A, Carvajal-Hausdorf, Daniel, McLaughlin, Joseph, Altan, Mehmet, Velcheti, Vamsidhar, Gaule, Patricia, Sanmamed, Miguel F, Chen, Lieping, Herbst, Roy S, Rimm, David L

“…To determine the expression level, associations, and biological role of PD-L1, IDO-1, and B7-H4 in non-small cell lung cancer (NSCLC). Using multiplexed…”
Get full text

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial by Ascierto, Paolo A, Mandalà, Mario, Ferrucci, Pier Francesso, Guidoboni, Massimo, Rutkowski, Piotr, Ferraresi, Virginia, Arance, Ana, Guida, Michele, Maiello, Evaristo, Gogas, Helen, Richtig, Erika, Fierro, Maria Teresa, Lebbè, Celeste, Helgadottir, Hildur, Queirolo, Paola, Spagnolo, Francesco, Tucci, Marco, Del Vecchio, Michele, Gonzales Cao, Maria, Minisini, Alessandro Marco, De Placido, Sabino, Sanmamed, Miguel F, Mallardo, Domenico, Curvietto, Marcello, Melero, Ignacio, Palmieri, Giuseppe, Grimaldi, Antonio M, Giannarelli, Diana, Dummer, Reinhard, Chiarion Sileni, Vanna

“…Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for -mutant metastatic melanoma. SECOMBIT is a randomized,…”
Get full text

Orchestrating immune check-point blockade for cancer immunotherapy in combinations by Perez-Gracia, Jose Luis, Labiano, Sara, Rodriguez-Ruiz, Maria E, Sanmamed, Miguel F, Melero, Ignacio

“…Highlights • Immunity against cancer is negatively regulated by lymphocyte surface receptors. • Cellular immunity against cancer can be unleashed by mAbs…”
Get full text

Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma by Alegre, Estibaliz, Sanmamed, Miguel F, Rodriguez, Carmen, Carranza, Omar, Martín-Algarra, Salvador, González, Alvaro

“…Malignant melanoma is an aggressive tumor that produces exosomes, which contain microRNAs (miRNAs) that could be of utility in following tumoral cell…”
Get full text

Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins by Sanmamed, Miguel F, Carranza-Rua, Omar, Alfaro, Carlos, Oñate, Carmen, Martín-Algarra, Salvador, Perez, Guiomar, Landazuri, Sara F, Gonzalez, Alvaro, Gross, Stefanie, Rodriguez, Inmaculada, Muñoz-Calleja, Cecilia, Rodríguez-Ruiz, María, Sangro, Bruno, López-Picazo, José M, Rizzo, Manglio, Mazzolini, Guillermo, Pascual, Juan I, Andueza, Maria Pilar, Perez-Gracia, Jose Luis, Melero, Ignacio

“…Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and…”
Get full text

CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation by Otano, Itziar, Azpilikueta, Arantza, Glez-Vaz, Javier, Alvarez, Maite, Medina-Echeverz, José, Cortés-Domínguez, Ivan, Ortiz-de-Solorzano, Carlos, Ellmark, Peter, Fritzell, Sara, Hernandez-Hoyos, Gabriela, Nelson, Michelle Hase, Ochoa, María Carmen, Bolaños, Elixabet, Cuculescu, Doina, Jaúregui, Patricia, Sanchez-Gregorio, Sandra, Etxeberria, Iñaki, Rodriguez-Ruiz, María E., Sanmamed, Miguel F., Teijeira, Álvaro, Berraondo, Pedro, Melero, Ignacio

“…CD137 (4-1BB; TNFSR9) is an activation-induced surface receptor that through costimulation effects provide antigen-primed T cells with augmented survival,…”
Get full text

Overview of Lung Cancer Immunotherapy by Sanmamed, Miguel F., Eguren-Santamaria, Iñaki, Schalper, Kurt A.

“…Anti-PD-(L)1 therapy represents a turning point in lung cancer immunotherapy, moving from previously ineffective enhancer strategies to immune checkpoints as…”
Get full text

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization by Sanmamed, Miguel F., Chen, Lieping

Get full text

Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism by Eguren-Santamaría, Iñaki, Rodríguez, Inmaculada, Herrero-Martin, Claudia, Fernández de Piérola, Eva, Azpilikueta, Arantza, Sánchez-Gregorio, Sandra, Bolaños, Elixabet, Gomis, Gabriel, Molero-Glez, Paula, Chacón, Enrique, Mínguez, José Ángel, Chiva, Santiago, Diez-Caballero, Fernando, de Andrea, Carlos, Teijeira, Álvaro, Sanmamed, Miguel F, Melero, Ignacio

“…Biomarkers for cancer immunotherapy are an unmet medical need. The group of Daniela Thommen at the NKI recently reported on novel methodologies based on…”
Get full text

Single-cell characterization of a model of poly I:C-stimulated peripheral blood mononuclear cells in severe asthma by Chen, Ailu, Diaz-Soto, Maria P, Sanmamed, Miguel F, Adams, Taylor, Schupp, Jonas C, Gupta, Amolika, Britto, Clemente, Sauler, Maor, Yan, Xiting, Liu, Qing, Nino, Gustavo, Cruz, Charles S Dela, Chupp, Geoffrey L, Gomez, Jose L

“…Asthma has been associated with impaired interferon response. Multiple cell types have been implicated in such response impairment and may be responsible for…”
Get full text

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells by Ochoa, Maria C., Perez-Ruiz, Elisabeth, Minute, Luna, Oñate, Carmen, Perez, Guiomar, Rodriguez, Inmaculada, Zabaleta, Aintzane, Alignani, Diego, Fernandez-Sendin, Myriam, Lopez, Ascension, Muntasell, Aura, Sanmamed, Miguel F., Paiva, Bruno, Lopez-Botet, Miguel, Berraondo, Pedro, Melero, Ignacio

“…Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of…”
Get full text